SEYSARA Drug Patent Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
When do Seysara patents expire, and when can generic versions of Seysara launch?
Seysara is a drug marketed by Almirall and is included in one NDA. There are four patents protecting this drug.
This drug has sixty-seven patent family members in twenty countries.
The generic ingredient in SEYSARA is sarecycline hydrochloride. One supplier is listed for this compound. Additional details are available on the sarecycline hydrochloride profile page.
DrugPatentWatch® Generic Entry Outlook for Seysara
Seysara was eligible for patent challenges on October 1, 2022.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be February 9, 2033. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for SEYSARA
International Patents: | 67 |
US Patents: | 4 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 50 |
Clinical Trials: | 1 |
Patent Applications: | 99 |
Drug Prices: | Drug price information for SEYSARA |
What excipients (inactive ingredients) are in SEYSARA? | SEYSARA excipients list |
DailyMed Link: | SEYSARA at DailyMed |


DrugPatentWatch® Estimated Generic Entry Opportunity Date for SEYSARA
Generic Entry Date for SEYSARA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for SEYSARA
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Derm Research, PLLC | Phase 4 |
Pharmacology for SEYSARA
Drug Class | Tetracycline-class Drug |
Mechanism of Action | P-Glycoprotein Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for SEYSARA
US Patents and Regulatory Information for SEYSARA
SEYSARA is protected by five US patents and one FDA Regulatory Exclusivity.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of SEYSARA is See Plans and Pricing.
This potential generic entry date is based on patent See Plans and Pricing.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting SEYSARA
Substituted tetracycline compounds
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: A METHOD FOR TREATING A BACTERIAL INFECTION IN INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS PATIENTS 9 YEARS OF AGE AND OLDER COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF SARECYCLINE HYDROCHLORIDE
Substituted tetracycline compounds for treatment of inflammatory skin disorders
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: A METHOD FOR TREATING A PATIENT 9 YEARS OF AGE AND OLDER SUFFERING FROM AN INFLAMMATORY SKIN DISORDER OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF SARECYCLINE HYDROCHLORIDE
Crystalline salts of (4S,4AS,5AR,12AS)-4-dimethylamino-3,10,12,12A-tetrahydroxy-7-[methoxy(met- hyl)amino)-methyl] acid amide and methods of using the same
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: A METHOD FOR TREATING ACNE IN INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS PATIENTS 9 YEARS OF AGE AND OLDER COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF SARECYCLINE HYDROCHLORIDE CRYSTALLINE SALT
Crystalline salts of (4S,4AS,5AR,12AS)-4-dimethylamino-3,10,12,12A-tetrahydroxy-7-[methoxy(met- hyl)amino)-methyl] acid amide and methods of using the same
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: A METHOD FOR TREATING A BACTERIAL INFECTION IN INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS PATIENTS 9 YEARS OF AGE AND OLDER COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF SARECYCLINE HYDROCHLORIDE CRYSTALLINE SALT
Substituted tetracycline compounds for treatment of inflammatory skin disorders
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: A METHOD FOR TREATING ACNE IN INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS PATIENTS 9 YEARS OF AGE AND OLDER COMPRISING ADMINISTERING SARECYCLINE HYDROCHLORIDE IN 60 MG, 100 MG OR 150 MG EQUIVALENT DOSES
FDA Regulatory Exclusivity protecting SEYSARA
NEW CHEMICAL ENTITY
Exclusivity Expiration: See Plans and Pricing
International Patents for SEYSARA
When does loss-of-exclusivity occur for SEYSARA?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Canada
Patent: 35876
Estimated Expiration: See Plans and Pricing
Croatia
Patent: 0191295
Estimated Expiration: See Plans and Pricing
Denmark
Patent: 07003
Estimated Expiration: See Plans and Pricing
European Patent Office
Patent: 07003
Estimated Expiration: See Plans and Pricing
Patent: 74908
Estimated Expiration: See Plans and Pricing
Hungary
Patent: 44536
Estimated Expiration: See Plans and Pricing
Japan
Patent: 74572
Estimated Expiration: See Plans and Pricing
Patent: 76082
Estimated Expiration: See Plans and Pricing
Patent: 14520077
Estimated Expiration: See Plans and Pricing
Patent: 17132775
Estimated Expiration: See Plans and Pricing
Patent: 19142867
Estimated Expiration: See Plans and Pricing
Patent: 21098695
Estimated Expiration: See Plans and Pricing
Lithuania
Patent: 07003
Estimated Expiration: See Plans and Pricing
Poland
Patent: 07003
Estimated Expiration: See Plans and Pricing
Portugal
Patent: 07003
Estimated Expiration: See Plans and Pricing
Slovenia
Patent: 07003
Estimated Expiration: See Plans and Pricing
Spain
Patent: 39626
Estimated Expiration: See Plans and Pricing
Turkey
Patent: 1911086
Estimated Expiration: See Plans and Pricing
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering SEYSARA around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Israel | 234755 | נגזרות טטרציקלין לטיפול בדלקות חיידקיות, נגיפיות וטפיליות (Tetracycline derivatives for the treatment of bacterial, viral and parasitic infections) | See Plans and Pricing |
Lithuania | 2120963 | See Plans and Pricing | |
Canada | 2673486 | UTILISATION DE COMPOSES A BASE DE TETRACYCLINE SUBSTITUEE DANS LE TRAITEMENT D'AFFECTIONS CUTANEES INFLAMMATOIRES (SUBSTITUTED TETRACYCLINE COMPOUNDS FOR TREATMENT OF INFLAMMATORY SKIN DISORDERS) | See Plans and Pricing |
Japan | 2015205939 | 細菌感染、ウイルス感染、および寄生虫感染の治療のためのテトラサイクリン誘導体 (TETRACYCLINE DERIVATIVE FOR TREATMENT OF BACTERIA INFECTION, VIRUS INFECTION AND PARASITE INFECTION) | See Plans and Pricing |
European Patent Office | 3488853 | COMPOSÉS DE TÉTRACYCLINE SUBSTITUÉS POUR LE TRAITEMENT DE TROUBLES INFLAMMATOIRES DE LA PEAU (SUBSTITUTED TETRACYCLINE COMPOUNDS FOR TREATMENT OF INFLAMMATORY SKIN DISORDERS) | See Plans and Pricing |
European Patent Office | 2109602 | DERIVÉS DE LA TETRACYCLINE POUR LE TRAITEMENT DE INFECTIONS BACTERIELLES, VIRALES ET PARASITIQUES (TETRACYCLINE DERIVATIVES FOR THE TREATMENT OF BACTERIAL, VIRAL AND PARASITIC INFECTIONS) | See Plans and Pricing |
Poland | 2109602 | See Plans and Pricing | |
>Country | >Patent Number | >Title | >Estimated Expiration |